85(R) - 2017
Relating to access to certain investigational drugs, biological products, and devices that are in clinical trials by patients with severe chronic diseases.
From the LBB: No significant fiscal implication to the State is anticipated.
Under current law, only patients with terminal illnesses are eligible to access investigational drugs, devices, or biological products in clinical trials. This bill would make patients with severe chronic diseases also eligible to try experimental drugs with informed consent and without interference from the state. This bill clarifies that it would not create a cause of action, and that action against physician's licenses is prohibited as long as the physician's recommendations meet the medical standard of care.
Vote Recommendation Notes
This bill represents a deregulation of the healthcare market that would help many people with chronic illnesses get access to drugs and therapies that could greatly help them without interference from the government, therefore, we support this bill.